Can a woman undergo radiofrequency ablation (RFA) to shrink uterine fibroids and then attempt pregnancy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Radiofrequency Ablation for Fibroids Before Pregnancy

Yes, radiofrequency ablation (RFA) of fibroids can be performed before attempting pregnancy, and emerging evidence suggests it is a safe, fertility-preserving option with pregnancy outcomes comparable to the general population.

Key Recommendation

Women can undergo transvaginal radiofrequency ablation (TRFA) for uterine fibroids and subsequently attempt pregnancy, with the critical caveat that they should wait at least 6 months after the procedure before conceiving to minimize miscarriage risk 1.

Evidence Supporting RFA Before Pregnancy

Pregnancy Outcomes

The most robust data comes from a 2025 study of 226 pregnancies after TRFA, which demonstrated 1:

  • No cases of uterine rupture (the most feared complication)
  • No placental abruption or fetal growth restriction
  • Miscarriage rate of 15.9% (comparable to general population)
  • Preterm delivery rate of 4.1%
  • Cesarean delivery rate of 26.4% (remaining 73.6% had vaginal deliveries)
  • One case of placenta accreta occurred only in a patient with prior open myomectomy history

Volume Reduction and Timing

TRFA achieves significant fibroid shrinkage 2, 1:

  • 72.4% volume reduction at 12 months
  • Median 49.4% reduction at 6 months
  • Median 69.8% reduction at 12 months

Critical timing consideration: Women with fibroids >58.6 mL had longer intervals to pregnancy, and miscarriage rates increased significantly when pregnancy occurred <5.7 months post-procedure 1. This suggests waiting 6+ months is essential for optimal fibroid resorption and uterine healing.

Fertility Outcomes

Recent 2026 data on infertile women with type 2-3 fibroids showed 3:

  • 68% pregnancy rate among those attempting conception
  • 52% live birth rate
  • 16% miscarriage rate
  • Most deliveries at full-term

A systematic review confirmed favorable reproductive safety profiles with successful pregnancies and no uterine ruptures 2.

How This Compares to Guideline-Recommended Options

The 2024 ACR guidelines do not specifically address RFA for fertility preservation, focusing instead on 4:

  • Myomectomy (hysteroscopic, laparoscopic, or open): Less than half of patients achieve pregnancy within 3 years, and less than half of those result in live births
  • UAE: 29.5-40.1% spontaneous pregnancy rates at 1-2 years, with 81% live birth rate among those who conceive
  • MRgFUS: Limited to case reports for fertility enhancement

RFA appears to offer comparable or superior outcomes to these established options, with the significant advantage of being minimally invasive and preserving uterine integrity without the risk of uterine rupture associated with myomectomy 4.

Clinical Algorithm for RFA Before Pregnancy

Patient Selection

RFA is most appropriate for:

  • Intramural fibroids (FIGO types 2-3) distorting the endometrial cavity
  • Fibroids <4 cm diameter (though larger can be treated with longer resorption times)
  • Women desiring fertility preservation
  • Those seeking to avoid surgical myomectomy

Procedure Approach

  • Ultrasound-guided transvaginal approach
  • Outpatient procedure with minimal complications
  • 22% may experience mild pain/minimal bleeding 3
  • 22% may require subsequent hysteroscopic removal of protruding fibroid tissue 3

Post-Procedure Timeline

  1. Immediate (1-3 months): Fibroid volume reduction begins; symptom improvement
  2. 3-6 months: Continued resorption; restoration of normal cavity anatomy 5
  3. 6+ months: Safe window to attempt conception 1
  4. Larger fibroids (>58.6 mL): May require 9-12 months before optimal conception window 1

Pregnancy Management

  • Standard prenatal care
  • No special restrictions beyond routine obstetric monitoring
  • Vaginal delivery is feasible (73.6% in largest series) 1
  • Cesarean delivery only for standard obstetric indications

Important Caveats

What RFA Does NOT Address

  • Submucosal fibroids requiring hysteroscopic removal: These may still need traditional myomectomy
  • Multiple large fibroids or very large uteri: Open myomectomy may be more appropriate 4
  • Subserosal fibroids: Laparoscopic approaches preferred 4

Reintervention Rate

The pooled reintervention rate is 15% 2, meaning some women may require additional treatment. However, this is comparable to or better than myomectomy recurrence rates.

Fertility Considerations

While RFA preserves fertility, it does not guarantee pregnancy. Women should undergo complete infertility workup to identify other potential causes before attributing infertility solely to fibroids 4.

Bottom Line

RFA (specifically transvaginal radiofrequency ablation) is a safe, effective, minimally invasive option for women with intramural fibroids who desire future pregnancy. The procedure achieves significant fibroid reduction, preserves uterine integrity, and results in pregnancy outcomes comparable to the general population with no increased risk of uterine rupture. The critical requirement is waiting at least 6 months post-procedure before attempting conception to allow adequate fibroid resorption and minimize miscarriage risk 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.